Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 3/2018

01-03-2018 | Original Article – Clinical Oncology

Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study

Authors: Friedemann Honecker, Ulrich Wedding, Gerd Kallischnigg, Axel Schroeder, Jörg Klier, Thomas Frangenheim, Lothar Weißbach

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2018

Login to get access

Abstract

Purpose

To gain knowledge about the factors associated with discontinuation of scheduled treatment in elderly men with castration-resistant prostate cancer (CRPC).

Methods

Patients ≥ 70 years with CRPC starting a new line of treatment were included in a prospective cohort study. A geriatric assessment (CGA) was performed at baseline, including comorbidity, mobility, functional/mental/nutritional status, as well as depression. Furthermore, pain intensity, quality of life, ECOG-performance status, and physicians’ and patients’ perception of health were documented. Reasons for and factors associated with discontinuation of scheduled treatment were analysed by univariate and multivariate analysis.

Results

After inclusion of 177 of 300 planned patients, the study was closed due to slow recruitment. 160 patients were eligible for final analysis. Median age was 77.5 years. 46% received chemotherapy, and 54% hormonal treatment. Discontinuation of scheduled treatment occurred in 91 patients (57.6%). The main reasons were progressive disease/death in 63%, adverse events/toxicity in 22%, and withdrawal of consent in 8%. In bivariate analyses, factors associated with discontinuation of treatment were age ≥ 80 years, ECOG PS ≥ 2, compromised/poor health status (physicians’/patients’ assessment), and compromised functional or nutritional status. In multivariate analysis, the only remaining factor independently associated with discontinuation of scheduled treatment was impairment of activities of daily living (ADL < 100 points) (OR = 4.2 for discontinuation; p < 0.05).

Conclusion

Despite limitations due to early termination of the study, our results demonstrate that discontinuation of scheduled treatment was common, and that compromised ADL seems to be a significant risk factor for treatment failure in elderly patients with CRPC.
Literature
go back to reference Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5(3):224–37CrossRefPubMed Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5(3):224–37CrossRefPubMed
go back to reference Bellera CA et al (2012) Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 23(8):2166–2172CrossRefPubMed Bellera CA et al (2012) Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 23(8):2166–2172CrossRefPubMed
go back to reference Decoster L et al (2015) Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol 26(2):288–300CrossRefPubMed Decoster L et al (2015) Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol 26(2):288–300CrossRefPubMed
go back to reference Droz JP et al (2014) Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 15(9):e404–e414CrossRefPubMed Droz JP et al (2014) Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 15(9):e404–e414CrossRefPubMed
go back to reference Extermann M, Boler I, Reich R et al (2012) Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer 1:3377–3386CrossRef Extermann M, Boler I, Reich R et al (2012) Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer 1:3377–3386CrossRef
go back to reference Hutchins LF et al (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061–2067CrossRefPubMed Hutchins LF et al (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061–2067CrossRefPubMed
go back to reference Pallis AG et al (2010) EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer 46(9):1502–1513CrossRefPubMed Pallis AG et al (2010) EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer 46(9):1502–1513CrossRefPubMed
go back to reference Wildiers H, Mauer M, Pallis A et al (2013) End points and trial design in geriatric oncology research: a Joint european organisation for research and treatment of cancer—alliance for clinical trials in Oncology—International Society of Geriatric Oncology Position Article. J Clin Oncol 31(29):3711–3718CrossRefPubMed Wildiers H, Mauer M, Pallis A et al (2013) End points and trial design in geriatric oncology research: a Joint european organisation for research and treatment of cancer—alliance for clinical trials in Oncology—International Society of Geriatric Oncology Position Article. J Clin Oncol 31(29):3711–3718CrossRefPubMed
Metadata
Title
Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study
Authors
Friedemann Honecker
Ulrich Wedding
Gerd Kallischnigg
Axel Schroeder
Jörg Klier
Thomas Frangenheim
Lothar Weißbach
Publication date
01-03-2018
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 3/2018
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-017-2577-1

Other articles of this Issue 3/2018

Journal of Cancer Research and Clinical Oncology 3/2018 Go to the issue